Health Technology Chugai Pharmaceutical Co., Ltd. Business Summary
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
Financial Highlights
Dec 2022
JPY USD Revenue 1,259.94B 9,579.32M Gross Profit 783,062M 5,953.59M Operating income 533,942M 4,059.54M Income before tax 531,166M 4,038.43M Net income 374,429M 2,846.77M EBITDA 565,376M 4,298.53M Diluted EPS 227.56 1.73 Dividends Per Share 78 0.59 Total Assets 1,869.75B 14,170.73M Total liabilities 445,371M 3,375.42M Total equity 1,424.38B 10,795.30M Operating cash flow 244,335M 1,857.67M Currency in JPY Currency in USD
Historical Data Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Revenue
579,787M
686,184M
786,945M
999,758M
1,259.94B
Gross Profit
316,025M
419,922M
511,775M
660,268M
783,062M
Operating income
129,225M
214,513M
306,882M
433,738M
533,942M
Income before tax
121,449M
207,893M
298,188M
419,385M
531,166M
Net income
92,488M
157,560M
214,733M
302,995M
374,429M
EBITDA
145,803M
240,914M
337,358M
464,606M
565,376M
Diluted EPS
56.26
95.80
130.53
184.16
227.56
Dividends Per Share
28.66
46.66
54.99
76
78
Total Assets
919,548M
1,058.91B
1,235.49B
1,538.69B
1,869.75B
Total liabilities
163,020M
204,929M
255,494M
350,677M
445,371M
Total equity
755,865M
853,985M
980,003M
1,188.01B
1,424.38B
Operating cash flow
119,269M
206,811M
205,101M
279,711M
244,335M
Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Revenue
5,249.65M
6,294.64M
7,370.57M
9,099.19M
9,579.32M
Gross Profit
2,861.43M
3,852.11M
4,793.31M
6,009.36M
5,953.59M
Operating income
1,170.06M
1,967.81M
2,874.27M
3,947.62M
4,059.54M
Income before tax
1,099.65M
1,907.08M
2,792.84M
3,816.98M
4,038.43M
Net income
837.42M
1,445.36M
2,011.20M
2,757.67M
2,846.77M
EBITDA
1,320.16M
2,210.00M
3,159.71M
4,228.56M
4,298.53M
Diluted EPS
0.50
0.87
1.22
1.67
1.73
Dividends Per Share
0.25
0.42
0.51
0.69
0.59
Total Assets
8,381.24M
9,743.86M
11,966.66M
13,361.93M
14,170.73M
Total liabilities
1,485.84M
1,885.70M
2,474.63M
3,045.26M
3,375.42M
Total equity
6,889.34M
7,858.15M
9,492.01M
10,316.67M
10,795.30M
Operating cash flow
1,079.91M
1,897.16M
1,920.98M
2,545.76M
1,857.67M
Valuation Measures
Dec 2022
PER 14.79 ROA 21.97% ROE 28.66% Operating margin 42.37% Profit margin 29.71%
Management
President, CEO & Representative Director:
Osamu Okuda
CFO, Manager-Information Technology & Accounting:
Itagaki Toshiaki
Executive Officer, GM-Research & Development:
Junichi Nezu
Senior Executive Officer & Head-Research:
Hisafumi Okabe
Executive Officer:
Toshihiko Komori Shareholders
Roche Holding AG (59.8%)
Nomura Asset Management Co., Ltd. (3.0%)
Chugai Pharmaceutical Co., Ltd. (2.0%)
Wellington Management Co. LLP (1.9%)
Nikko Asset Management Co., Ltd. (1.4%)
Daiwa Asset Management Co. Ltd. (1.4%)
The Vanguard Group, Inc. (1.3%)
Harding Loevner LP (0.9%)
BlackRock Fund Advisors (0.8%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.7%)
Contact Details Website: http://www.chugai-pharm.co.jp Address:
Nihonbashi Mitsui Tower, 15/F,
2-1-1 Nihonbashi-Muromachi,
Tokyo,
103-8324,
Japan
Phone:
+81.3.3281.6611
Related Companies
Chugai Pharmaceutical Co. Ltd. /Bonviva Drug Business/
Chugai Pharma Europe Logistics SAS
Chugai Pharma Germany GmbH
Chugai Distribution Co., Ltd.
Medical Culture YK
Chugai Business Support Co., Ltd.
Chugai Clinical Research Center Co., Ltd.
Chugai Pharma Technology Taizhou Co., Ltd.
Chugai Pharmaceutical Restricted Stock Compensation Plan
Chugai Pharma Consulting (Shanghai) Co., Ltd.
Chugai Pharma R&D Taiwan Ltd.
Chugai Pharma China Co., Ltd.
Chugai Pharma Science (Beijing) Co., Ltd.
Chugai Pharma Taiwan Ltd.
Chugai Pharmabody Research Pte Ltd.
Pharmalogicals Research Pte Ltd.
Forerunner Pharma Research Co., Ltd.
Chugai Research Institute for Medical Science, Inc.
Chugai Pharma Manufacturing Co., Ltd.
Chugai Pharmaceutical Employee Stock Ownership Plan
Chugai Pharma U.K. Ltd.
Chugai Pharma France SAS
Chugai Biopharmaceuticals, Inc.
Chugai Pharma USA LLC
Nippon Roche KK
Competitors
Horizon Therapeutics Public Limited Company
Regeneron Pharmaceuticals, Inc.
Springworks Therapeutics, Inc.
Genelux Corp.
Celldex Therapeutics, Inc.
Apellis Pharmaceuticals, Inc.
Cara Therapeutics Inc
Immunic, Inc.
Equillium, Inc.
UBI Pharma, Inc.
Context Therapeutics, Inc.
Nuvalent, Inc. Class A
PanGen Biotech, Inc.
ACELYRIN, INC.
Acumen Pharmaceuticals, Inc.
Ardelyx, Inc.
ProMIS Neurosciences Inc.
Copyright © 2023 FactSet Research Systems Inc. All rights reserved.
Last Updated on 22 Sep, 2023
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more